- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07910864
Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Effect of Preoperative Ultrasound-Guided Bilateral Greater Occipital Nerve Block on Postoperative Headache Following Endovascular Coiling of Unruptured Intracranial Aneurysms: A Prospective, Randomized, Sham-Controlled Trial
Postoperative headache is a common complication following endovascular coil embolization of intracranial aneurysms and may increase analgesic requirements, impair patient comfort, and contribute to hemodynamic instability.
The greater occipital nerve (GON) has anatomical and functional connections with the trigeminocervical complex, suggesting that greater occipital nerve blockade may modulate headache-related pain pathways. However, the effectiveness of prophylactic greater occipital nerve block in patients undergoing elective endovascular coiling of unruptured intracranial aneurysms remains uncertain.
This prospective, randomized, sham-controlled, single-center clinical trial aims to investigate whether preoperative ultrasound-guided bilateral greater occipital nerve block reduces postoperative headache intensity during the first 24 hours following endovascular coil embolization.
A total of 76 patients will be randomly allocated in a 1:1 ratio to receive either ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine or bilateral superficial sham injections with 0.9% normal saline.
The active intervention will consist of 3 mL of 0.25% bupivacaine administered on each side in the fascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The control intervention will consist of a superficial subcutaneous injection of 0.5 mL of 0.9% normal saline on each side.
All participants will receive standardized general anesthesia and postoperative multimodal analgesia.
The primary outcome will be the time-weighted average resting pain score during the first 24 postoperative hours, calculated from the area under the Numeric Rating Scale (NRS) pain score-time curve.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Ömer Keklicek, Principal Investigator
- Telefonní číslo: +905399291702
- E-mail: drokeklicek@gmail.com
Studijní místa
-
-
Konya
-
Konya, Konya, Turecko (Türkiye), 42090
- Nábor
- Konya City Hospital
-
Kontakt:
- Ömer Keklicek
- Telefonní číslo: +905399291702
- E-mail: drkeklicek@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Patients aged 18-65 years.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Patients scheduled for elective endovascular coil embolization of a unilateral unruptured intracranial aneurysm under general anesthesia.
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- Refusal to provide informed consent or subsequent withdrawal of consent.
- Ruptured intracranial aneurysm or acute subarachnoid hemorrhage requiring emergency intervention.
- Clinical contraindications to greater occipital nerve block, including infection or skin lesions at the injection site, local anesthetic allergy, or anatomical conditions preventing safe needle placement.
- Platelet count below 100,000/mm³, international normalized ratio (INR) greater than 1.5, activated partial thromboplastin time (aPTT) greater than 1.5 times normal, or clinically significant coagulopathy.
- Antithrombotic or antiplatelet treatment that does not meet the predefined safety intervals for deep peripheral nerve blocks according to the ASRA 2025 and ESAIC/ESRA guidelines.
- Moderate-to-severe preoperative headache, defined as a resting Numeric Rating Scale score of 3 or higher.
- Known history of severe hypersensitivity or allergic reactions to local anesthetics.
- Chronic opioid use, chronic pain syndrome, or regular analgesic use that may substantially interfere with postoperative pain assessment.
- Uncontrolled hypertension or clinically significant uncontrolled cardiac arrhythmia.
- Pregnancy or breastfeeding.
- Neurological deficits, aphasia, impaired consciousness, cognitive impairment, or communication difficulties preventing reliable pain assessment using the Numeric Rating Scale.
- Body mass index greater than 35 kg/m².
- Clinical circumstances requiring initiation of intravenous unfractionated heparin within one hour after the planned study-related needle intervention.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Postoperative headache is a common complication following endovascular coil embolization of intracra
Participants assigned to the experimental group will receive preoperative ultrasound-guided bilateral greater occipital nerve block with 0.25% bupivacaine before induction of general anesthesia. A total of 3 mL of 0.25% bupivacaine (7.5 mg) will be administered on each side into the interfascial plane between the semispinalis capitis and obliquus capitis inferior muscles. The total bilateral dose will be 15 mg of bupivacaine in 6 mL. The intervention will be performed while the patient is awake and able to communicate, without routine deep sedation. All participants will subsequently receive standardized general anesthesia and postoperative multimodal analgesia. |
Ultrasound-guided bilateral greater occipital nerve block will be performed before general anesthesia induction using a high-frequency linear ultrasound transducer. The greater occipital nerve will be identified between the semispinalis capitis and obliquus capitis inferior muscles. A 25-gauge, 50-mm echogenic needle will be advanced under continuous ultrasound guidance using an in-plane approach. Following color Doppler assessment and negative aspiration, 3 mL of 0.25% bupivacaine (7.5 mg) will be injected slowly and incrementally on each side. The total bilateral dose will be 15 mg of bupivacaine. |
|
Falešný srovnávač: Bilateral Superficial Sham Injection
Participants assigned to the control group will receive bilateral superficial subcutaneous sham injections with 0.9% normal saline before induction of general anesthesia. Following the same general preparation, positioning, and ultrasound examination as the experimental group, 0.5 mL of 0.9% normal saline will be injected subcutaneously on each side of the occipital region using a short 27-gauge needle. The total bilateral injection volume will be 1 mL. The needle will not be advanced into the deep interfascial plane, and no injection will be performed around the greater occipital nerve. All participants will receive standardized general anesthesia and postoperative multimodal analgesia. |
A bilateral superficial subcutaneous sham injection will be performed before general anesthesia induction. Following standardized positioning, skin antisepsis, and ultrasound examination, a short 27-gauge needle will be used to administer 0.5 mL of 0.9% normal saline subcutaneously on each side of the occipital region. The total bilateral injection volume will be 1 mL. The needle will not be advanced into the deep interfascial plane, and the greater occipital nerve will not be directly targeted. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Time-Weighted Average Resting Pain Score During the First 24 Postoperative Hours
Časové okno: From postoperative hour 0 to postoperative hour 24
|
Postoperative resting pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). NRS scores will be recorded at postoperative hours 0, 2, 4, 6, 8, 12, and 24. The area under the NRS pain score-time curve (AUC0-24) will be calculated using the linear trapezoidal method and divided by 24 hours to obtain the time-weighted average NRS score. The resulting patient-level value will range from 0 to 10, with higher scores indicating greater overall postoperative pain intensity. |
From postoperative hour 0 to postoperative hour 24
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Bolest
- Neurologické projevy
- Cerebrovaskulární poruchy
- Onemocnění mozku
- Onemocnění centrálního nervového systému
- Nemoci nervového systému
- Cévní onemocnění
- Kardiovaskulární choroby
- Pooperační komplikace
- Patologické procesy
- Intrakraniální arteriální onemocnění
- Aneuryzma
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- Bolest, pooperační
- Intrakraniální aneuryzma
Další identifikační čísla studie
- 2026_KAEK-64_28
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .